Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs, including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma G12D protein for the treatment of cancers with the G12D mutation comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), which are investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.…
Arvinas to Present at Jefferies Global Healthcare Conference
Arvinas (NASDAQ: ARVN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 246 employees.
The shares were at 6.460 USD on 20 November 2026, down 39.2% over 52 weeks. Its 52-week range is 6.330 USD to 14.51 USD: the price is 55.5% below the high and 2.1% above the low.
Its market capitalisation is 423.03M USD.
Arvinas reports return on equity of -18.6%, an operating margin of -10.1% and revenue down 98.8% year over year.
It holds more cash than debt, a net cash position of 551.00M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 13 analysts cover the stock, with an average rating of Buy; their mean price target of 14.00 USD is 116.7% above the current price. The next earnings report is expected on 23 February 2027.